Morag Peberdy > Goodwin > London, England > Lawyer Profile
Goodwin Offices

Sancroft, 10-15 Newgate Street
London
EC1A 7AZ
England
- Firm Profile
- Go to...
Morag Peberdy

Position
Partner
Career
Morag Peberdy has specialized in life sciences work for more than twenty years. She advises biotech and pharmaceutical companies, ranging from start-ups through to big pharma, on drafting and negotiating intellectual property-related agreements. She has particular expertise in foundational IP licenses and strategic drug discovery collaborations.
In her work with innovative multi-national, national, and start-up life sciences companies, Morag regularly:
- Provides strategic advice on licensing and partnering
- Assists clients to put in place R&D and collaboration agreements, patent licenses, intellectual property pipeline arrangements, joint ventures, option agreements, strategic alliances, and other commercial and IP-related contracts; and
- Advises on intellectual property issues arising in corporate transactions, including mergers and acquisitions, initial public offerings, venture capital investments, royalty monetizations and restructurings
Morag had a background in biological sciences prior to qualifying as a lawyer and sits on the PLC Life Sciences Consultation Board and the Intellectual Property Advisory Committee of the Bio Industry Association, advising across the spectrum of intellectual property issues impacting life science companies.
Morag’s insight into both contentious and non-contentious IP matters enables her to bring a valuable perspective and breadth of knowledge to strategic intellectual property issues, which is invaluable in assisting clients’ business objectives.
Education
Diploma, Intellectual Property Law and Practice, University of Bristol, Bristol, UK; Diploma, Legal Practice, Nottingham Law School (Distinction); Post-Graduate Diploma in Law, Nottingham Law School (Distinction); MA, Biological Sciences, University of Oxford (First Class Honors)
Top Tier Firm Rankings
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)
- Corporate and commercial > EU and competition
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)
- Risk advisory > Regulatory investigations and corporate crime (advice to corporates)
- Corporate and commercial > Private equity: transactions - mid-market deals (up to £500m)
- Investment fund formation and management > Real estate funds
- Corporate and commercial > Venture capital
Firm Rankings
- Corporate and commercial > M&A: Lower Mid-Market Deals, £100m-£750m
- Investment fund formation and management > Private funds
- Real estate > Commercial property: investment
- TMT (technology, media and telecoms) > Fintech: corporate and commercial
- Industry focus > Hospitality and leisure
- Industry focus > Life sciences and healthcare
- Finance > Acquisition finance
- Corporate and commercial > Corporate tax
- Investment fund formation and management > Fund finance
- Finance > Corporate restructuring & insolvency
- Risk advisory > Data protection, privacy and cybersecurity
- TMT (technology, media and telecoms) > IT and telecoms
- Corporate and commercial > Private equity: transactions – high-value deals (£500m+)
- Real estate > Property finance
- Dispute resolution > Commercial litigation: premium
- Employment > Employers
- Corporate and commercial > Equity capital markets – small-mid cap
- Corporate and commercial > EU and competition
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)
- Risk advisory > Regulatory investigations and corporate crime (advice to corporates)